Altered p21(WAF1/CIP1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma

Cancer Letters

Volumn 154, Issue 1, 2000, Pages 85-91

  Li, Xin ^a   Hui, Ai Min ^a   Takayama, Tadatoshi ^a   Cui, Xing ^a   Shi, Yazhou ^a   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Extrahepatic bile duct carcinoma; p21(WAF1 CIP1); p53; Survival

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034212939     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00383-9     Document Type: Article

References (23)

1. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
2. Nasmyth K., Hunt T. Dams and sluices. Nature. 366:1993;634-635.
3. El-deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
4. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
5. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
6. El-deiry W.S. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227:1998;121-137.
7. WAF1. Cancer Res. 55:1995;4536-4539.
8. Shiohara M., El-deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.L., Vogelstein B., Koeffler H.P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
9. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., Kaibara N., Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 79:1997;2067-2072.
10. WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J. Pathol. 187:1999;302-307.
11. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer. 74:1996;208-215.
12. CIP1/WAF1 protein accumulation in head-and-neck cancer. Int. J. Cancer. 74:1997;383-389.
13. WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst. 90:1998;1072-1079.
14. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;5545-5549.
15. Maki C.G., Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17:1997;355-363.
16. Diamantis I., Karamitopoulou E., Perentes E., Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 22:1995;774-779.
17. Suto T., Sugai T., Nakamura S., Funato O., Nitta H., Sasaki R., Kanno S., Saito K. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer. 82:1998;86-95.
18. Japanese Society of Biliary Surgery. General Rules for Surgical and Pathological Studies on Cancer of Biliary Tract. 3:1993;Kanehara, Tokyo.
19. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumors. 1997;Wiley-Liss Inc, New York.
20. Kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology. 30:1999;1167-1173.
21. Yang G.Y., Zhang Z., Liao J., Seril D., Wang L.D., Goldstein S., Yang C.S. Immunohistochemical studies on Waf1 p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int. J. Cancer. 72:1997;746-751.
22. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:1997;2090-2100.
23. WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology. 25:1997;575-579.